Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Chinook Therapeutics (KDNY)
NASDAQ:KDNY
Chinook Therapeutics (KDNY) Stock Price & Analysis
457 Followers
KDNY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.08 - $27.44
Previous Close$25.21
Volume1.27M
Average Volume (3M)677.18K
Market Cap
$1.69B
Enterprise Value$1.37B
Total Cash (Recent Filing)$350.38M
Total Debt (Recent Filing)$38.26M
Price to Earnings (P/E)-7.9
Beta0.70
Next Earnings
Nov 09, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding66,889,369
10 Day Avg. Volume613,082
30 Day Avg. Volume677,179
Standard Deviation0.22
R-Squared0.00111
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.88
Price to Sales (P/S)922.47
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue261.30
Enterprise Value/Gross Profit224.24
Enterprise Value/Ebitda-6.58
Forecast
1Y Price Target
$36.29Price Target Upside44.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Chinook Therapeutics News
Pre-EarningsKDNY Upcoming Earnings Report: What to Expect?
Stock Analysis & IdeasTipRanks ‘Perfect 10’ List: These 2 Top-Rated Stocks Could Be Long-Term Winners
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KDNY FAQ
What was Chinook Therapeutics’s price range in the past 12 months?
Chinook Therapeutics lowest stock price was $15.08 and its highest was $27.44 in the past 12 months.
What is Chinook Therapeutics’s market cap?
Currently, no data Available
When is Chinook Therapeutics’s upcoming earnings report date?
Chinook Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is in 156 days.
How were Chinook Therapeutics’s earnings last quarter?
Chinook Therapeutics released its earnings results on May 09, 2023. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.795 by -$0.055.
Is Chinook Therapeutics overvalued?
According to Wall Street analysts Chinook Therapeutics’s price is currently Undervalued.
Does Chinook Therapeutics pay dividends?
Chinook Therapeutics does not currently pay dividends.
What is Chinook Therapeutics’s EPS estimate?
Chinook Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chinook Therapeutics have?
Chinook Therapeutics has 66,889,366 shares outstanding.
What happened to Chinook Therapeutics’s price movement after its last earnings report?
Chinook Therapeutics reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.795. Following the earnings report the stock price went up 7.481%.
Which hedge fund is a major shareholder of Chinook Therapeutics?
Among the largest hedge funds holding Chinook Therapeutics’s share is Baker Bros Advisors LP. It holds Chinook Therapeutics’s shares valued at 34M.
---
Chinook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.29 (44.58% Upside)
$36.29 (44.58% Upside)
Blogger Sentiment
Bullish
KDNY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.36%
12-Months-Change
Fundamentals
Return on Equity
-51.56%
Trailing 12-Months
Asset Growth
2.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Chinook Therapeutics
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
---
Top 5 ETFs holding KDNY
Vanguard Total Stock Market ETF
$34.53M
iShares Biotechnology ETF
$8.26M
Vanguard Health Care ETF
$2.91M
iShares Core S&P Total U.S. Stock Market ETF
$1.10M
iShares NASDAQ US Biotechnology UCITS ETF
$757.65K
Up to five ETFs with an Outperform Smart Score that hold KDNY. The ETFs are listed according to market value of KDNY within the ETF
---
---